Sunovion [SEP] inception
Sunovion
Sunovion Pharmaceuticals, Inc. (former NASDAQ: "SEPR"), known until October 12, 2010 as Sepracor, Inc. prior to its acquisition by Sumitomo Dainippon Pharma of Japan, is a pharmaceutical company founded in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler. It was originally located in Princeton, New Jersey and then re-located to Marlborough, Massachusetts. In addition to its headquarters location in Marlborough, Massachusetts, Sunovion has locations in London, England, Mississauga, Ontario Canada, and Fort
of SEP-363856 has not been reported, though the developer has suggested that the pharmacokinetic data supports once daily dosing.
Chemistry.
The chemical structure and formula of SEP-363856 is not in the public domain.
Research.
As of 2018, Sunovion, the maker of another antipsychotic called lurasidone (Latuda), is conducting clinical trials on SEP-363856 in partnership with the preclinical research company PsychoGenics. The U.S. Food and Drug Administration has granted SEP-363856 the Breakthrough Therapy Designation. In addition to schizophrenia, SEP-363856 is also being studied for